Mammary Cell News Volume 6.17 | May 8 2014

Hypoxia-Inducible Factor-Dependent Signaling between Triple-Negative Breast Cancer Cells and Mesenchymal Stem Cells Promotes Macrophage Recruitment
Researchers identified signals that are exchanged between breast cancer cells (BCCs) and mesenchymal stem cells (MSCs). This signaling increases the recruitment of both MSCs and macrophages to primary tumors and increases metastasis of BCCs to lymph nodes and lungs. [Proc Natl Acad Sci USA] Abstract

Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human Cancer
Ablation of FAM83A (Family with sequence similarity 83, member A) or FAM83D from breast cancer cells resulted in diminished MAPK signaling with marked suppression of growth in vitro and tumorigenicity in vivo. [Cancer Res] Abstract

The E2F Activators Signal and Maintain Centrosome Amplification in Breast Cancer Cells
Since centrosome amplification is frequent in premalignant lesions and breast tumors, it is proposed to play a central role in breast tumorigenesis, a hypothesis that remains to be tested. Because E2Fs are deregulated in Her2+ cells displaying centrosome amplification, investigators addressed whether they signal this abnormal process. [Mol Cell Biol] Abstract

Acute and Chronic Cadmium Exposure Promotes E-Cadherin Degradation in MCF7 Breast Cancer Cells
Researchers aimed to determine if cadmium exposure – both acute and chronic – contributes to breast cancer progression by interfering with the normal functional relationship between E-cadherin and β-catenin. [Mol Carcinog] Abstract

LRP1-Dependent Pepsin Clearance Induced by 2-Hydroxycinnamaldehyde Attenuates Breast Cancer Cell Invasion
Scientists examined whether 2′-hydroxycinnamaldehyde, acting as a Michael acceptor, interferes with the ligand binding of low-density lipoprotein receptor-related protein 1 to mediate breast cancer cell invasion. [Int J Biochem Cell Biol] Abstract

Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation
Investigators used an approach involving a quantitative model of cell-state transitions in vitro to gain insights into how SLUG/SNAI2, a key developmental transcription factor, modulates mammary epithelial stem cell activity and differentiation in vivo. [Stem Cell Rep] Full Article | Press Release

CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer
Scientists showed that Ctcf hemizygous knockout mice are markedly susceptible to spontaneous, radiation-, and chemically induced cancer in a broad range of tissues. [Cell Rep]
Full Article | Graphical Abstract | Press Release

Wnt-Responsive Cancer Stem Cells Are Located Close to Distorted Blood Vessels and Not in Hypoxic Regions in a p53-Null Mouse Model of Human Breast Cancer
Researchers analyzed the relationship between a Wnt-responsive, cancer stem cells-enriched population and the tumor vasculature using p53-null mouse mammary tumors transduced with a lentiviral Wnt signaling reporter. [Stem Cells Transl Med] Abstract

CLINICAL RESEARCH

Trastuzumab Emtansine versus Treatment of Physician’s Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomized, Open-Label, Phase III Trial
Investigators compared trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxic agent DM1 linked to trastuzumab, with treatment of physician’s choice in this population of patients. [Lancet Oncol] Abstract

Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomized Phase II Trial
Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. Investigators aimed to assess the efficacy of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer. [Lancet Oncol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

IceCure Medical, Inc. Announces Commencement of ICE3 Clinical Trial for Breast Cancer
IceCure Medical, Inc. announced the beginning of a multi-centered clinical trial which will study the effect of percutaneous cryoablation on malignant breast tumors. [IceCure Medical, Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells? Request your free wallchart.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Postdoctoral Position – Breast Cancer Research (University of Oklahoma Health Sciences Center)

Postdoctoral Fellow – Cancer Biology (University of Cincinnati)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

PhD Position – Breast Cancer Translational Research Laboratory (Jules Bordet Institute)

Postdoctoral Position in Stem Cell and Cancer (Harvard Medical School)

Junior Faculty Position – Breast Pathology (Northwestern University)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Research Technologist – hPSC (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.